Mohamed Hamdy Elkarow
Amr Hamdy- 1Department of General Surgery, Ain Shams University, Cairo, Egypt
- 2Faculty of Medicine, Ain Shams University, Cairo, Egypt
- 3Department of Obstetrics & Gynecology, Shoubra General Hospital, Ministry of Health and Population, Cairo, Egypt
Covid19 is a worldwide pandemic challenge that started in Wuhan, China and spread to almost all countries on the planet within a few months. The causative virus was found to be highly contagious and, until now, considerably difficult to contain. A look at the epidemiological distribution of the disease over the planet has raised a number of questions whose answers could help us understand the behavior of the virus and consequently leads us to possible means of limitation of its spread or even flattening of the curve of morbidity and mortality. After the third decade of life, there is a progressive decline of growth hormone (GH) secretion by approximately 15% for every decade of adult life. The data from highly affected countries suggest a more aggressive course in the elderly, a double-time affection of males more than females, and the vulnerability of some risk groups of patients. Our observation is that GH deficiency is a common factor in all vulnerable patient groups. We think that there is a need for studying the role of growth hormone in the unique epidemiological pattern of Covid-19 so that it might help in the early detection and management of the high-risk groups as appropriate.
Introduction
Coronavirus disease (Covid-19) is a worldwide pandemic challenge that started in Wuhan, China, in December 2019 and spread to most countries of the world within a few months. The World Health Organization (WHO) declared SARS-CoV-2 as an international public health emergency in January 2020 and as a pandemic in March 2020. Currently, the COVID-19 pandemic has resulted in more than 6 million confirmed cases and more than 370,000 deaths globally. Despite the strict measures adopted by several governments, the disease has imposed an unprecedented burden on health care workers even in countries that have advanced health care services. The socioeconomic impact of the pandemic increased the need for a solution that allows safe easing of restrictive health measures. Primarily, most of the urgent efforts exerted by research centers are directed toward creating a proper vaccine or efficient medical treatment for the virus. However, preventive measures based on understanding the epidemiology of the disease can also be of utmost importance in attenuating its spread.
In this article, we discuss a brief perspective about the possible role of relative growth hormone deficiency (GHD) and/or resistance in the high-risk groups of patients for Covid-19 disease. Our observation is based on the updated epidemiological data of the pandemic and the known levels of growth hormone (GH) in different risk groups of patients as well as the effect of GH on the immune system.
Why Elderly People Are at a Higher Risk?
Data from the World Health Organization (WHO) reports that the disease affects elderly people much more than young people and children. This pattern is not common in most infectious diseases, which usually affect those age groups who are supposed to be still in the stage of building up their immunity more. For many communicable diseases, young adults and children are at greater risk, for instance, in the largest pandemic in recent history: During the Spanish flu in 1918, children and young adults were at the greatest risk for the pandemic (1).
On the contrary, data from the Chinese Center for Disease Control and Prevention report that children under 19 years of age constitute 2% of the total number (72,314) of Covid-19 cases recorded by February 20, 2020. A very small percentage of those patients aged under 19 years have suffered severe (2.5%) or critical disease (0.2%) (2). On the other hand, severity and case fatality of COVID-19 progressively increased with advancing age. The recorded increase in severity with age is reflected in case reports, in which the mean age was in the range of 50–60 years (3).
There is probably a lacking factor in the elderly that makes them more vulnerable to the disease severity. Growth hormone (GH) level declines in the serum as man advances in age. After the third decade of life, there is a progressive decline of GH secretion by approximately 15% for every decade of adult life. Integrated measurements of daily GH secretion demonstrate that secretion peaks at puberty at about 150 microgram/kg/day and then decreases to approximately 25 microgram/kg/day by age 55 (4). The pediatric age group usually exhibits atypical clinical manifestations of COVID-19, which are mainly milder compared with those of adult patients (5–7), and occurrence of pediatric severe and life-threatening forms are very scarce (8, 9). Children with comorbidities, including chronic kidney and lung disease, diabetes, obesity, sickle cell anemia, malignancy, immune disorders, chromosomal abnormalities, heart disease, and congenital malformations, are more likely to suffer from the severe form of COVID-19 (5–8). Interestingly, infants (less than 12 months) exhibit a more severe form of the disease than other pediatric age groups. GH levels are high in the mid-term fetus and at birth and then decline sharply in the first few weeks and more slowly over the next few months, reaching prepubertal levels by around the age of 6 months (10). The current data suggests that children may get infected but be less symptomatic with less case fatality. The real incidence of infection in children may be unveiled through large screening studies, involving serological tests. The regulation of the GH/IGF-I axis depends on the integrity of the hypothalamus, pituitary, and liver. During aging, the leading factors that contribute to the decline in GH/IGF-I include the changes in signal to the somatotrophs from growth hormone-releasing hormone (GHRH) and somatostatin (SS). Other important factors, such as body composition, exercise, diet, and sleep play a significant role in the age-related decline of the GH level. The phenotypic similarities between aging and adult growth hormone deficiency syndrome combined with this decrease in GH/IGF-I with aging have raised the question of whether aging is a GH deficient state (11). It is worth noting that the reported curve of COVID-19 morbidity and mortality, matches well the pattern of decline of GH level throughout the life of human subjects.
Why Male Gender Is at a Higher Risk?
Why does the disease affect men at twice the amount it affects women? The emerging trend is that men are much more likely to die of the disease than women. Data from China first revealed a gender gap in death rate with 64% of male patients dying compared to 36% of women, according to the Global Health 50/50 initiative. Figures from Italy, Spain, France, Germany, and the USA, have confirmed the pattern. In the two most affected European countries, 71% of the Covid-19 deaths in Italy were male, and in Spain, almost twice as many men as women have died (12).
The symmetric model in different countries suggests the presence of a relative protective factor in the female gender. It has long been known that GH secretion is greater in women than in men despite similar reference ranges of serum insulin-like growth factor (IGF)-I in adult men and women. It has also been reported that sex steroids influence not only GH secretion but also the local synthesis of IGF-I in target tissues and the expression of the GH receptor in various other tissues (13). The normal range for GH level is typical: for adult males, 0.4 to 10 nanograms per milliliter (ng/mL); for adult females, 1 to 14 ng/mL; and for children, 10 to 50 ng/mL (14). As men grow older, testosterone levels decline gradually with free testosterone concentrations falling by about 50% between ages 25 and 75 years (15). The gradual decline of testosterone with aging is parallel to the age-related fall in growth hormone secretion levels, resulting in lower circulating levels of IGF-1 (16). Testosterone exerts a stimulatory effect on growth hormone secretion at the pituitary level, which is called a “push effect.” On the other hand, estrogen increases GH secretion only through its inhibitory effect on IGF-1 production in the liver with resultant feedback stimulation of GH release from the pituitary: “a pull effect” (17). Spontaneous and stimulated GH secretion is higher in young women than in postmenopausal women or young men. The difference was found to be strongly correlated with estrogen concentrations (18). GH secretion declines more rapidly with increasing age in men than in women between the third and fifth decades (19). Although spontaneous GH secretion falls progressively with advancing years, an abrupt reduction over the menopausal years does not occur, and most of the change is explained by age-associated increases in the body or abdominal fat (20, 21).
GH circulates in the blood bound to a high-affinity binding protein (GHBP). The liver is a major source of GHBP, which is derived from proteolytic cleavage of the extracellular domain of the GH receptor (GHR). GHBP alters the distribution and pharmacokinetics of GH and is likely to modulate GH action (22). Serum GHBP concentrations are significantly higher in women than in men (23).
There is strong evidence that GH negatively regulates many pro-inflammatory cytokines. Serum levels of CRP, IL-6, and TNF-α are increased in adults with GH deficiency and fall in response to GH replacement (24, 25). Monocyte production of IL-6 and TNF-α is increased in patients with GH deficiency and reduced by GH treatment (24). Levels of CRP are low in active acromegaly and increase with the disease control (26). These data indicate that GH directly or indirectly reduces inflammation by modulating serum levels of cytokines and markers of inflammation. Meanwhile, there is evidence that estrogen inhibits signaling of several members of the cytokine receptor family, including prolactin, IL-6, and leptin (27). Thus, deficiency in both GH and estrogen is associated with increased serum concentrations of CRP, IL-6, and TNF-α. Recent data suggests that the IL-6-JAK-STAT3 axis is closely involved in the development of severe COVID-19 disease (28, 29). High serum IL-6 has been commonly reported in patients with severe COVID-19 and correlated significantly with mortality (30, 31). The inhibitory action of estrogen on JAK2-mediated signal transduction may have broader implications beyond GH action given that the JAK/STAT/SOCS systems are integral components of the cytokine receptor signaling (16). Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19 has recently been presented as an attractive therapeutic strategy (32).
Growth Hormone Profile in Potential Risk Factors for Severity of COVID-19 Illness
COVID-19 disease severity and mortality were reported to be increased with some risk factors, such as morbid obesity, hypertension, diabetes, respiratory disorders, excessive alcohol intake, and chronic liver and kidney disease (33–35).
Morbid Obesity
Morbid obesity occurs when the body mass index (BMI) exceeds 35. It constitutes a risk factor for SARS-CoV-2 severity, which requires increased attention to preventive measures in susceptible individuals (36). In morbid obesity, there is markedly decreased GH secretion. In addition, for both adults and children, the greater the BMI, the lower the GH response to provocative stimuli (37). In obesity, both the spontaneous (38, 39) and stimulated (40) pulsatile patterns of GH secretion controlled by the hypothalamus are blunted. The accumulation of truncal obesity, particularly visceral adipose tissue mass, was found to be a stronger negative determinant of GH secretion than other factors, such as age, sex, or generalized obesity (41, 42). GH deficiency effectively enhances insulin resistance and visceral obesity through increasing cortisol production in key target tissues, including liver and adipose tissue (43). In the peripheral tissues, corticosteroid hormone action is determined, in part, through the activity of 11beta-hydroxysteroid dehydrogenases (11beta-HSD). Two iso-zymes of 11 beta-HSD interconvert hormonally active cortisol (F) and inactive cortisone (E). 11beta-HSD type 1 principally activates F from E in the liver and adipose tissue while 11beta-HSD type 2 inactivates F to E in the kidney and placental tissue. GH acting via IGF-1, inhibits 11beta-HSD1, resulting in a shift in cortisol metabolism favoring cortisone production (44). Patients with truncal obesity but with no evidence of hypopituitarism have relative GH deficiency, and it is exciting that low-dose GH treatment in this group, by inhibiting cortisol generation within omental fat, may offer an effective therapeutic approach (43).
Diabetes Mellitus
Diabetes mellitus is associated with increased severity and mortality of disease in COVID-19 pneumonia (45). Although GH excess, such as in patients with acromegaly, predisposes to diabetes, studies report that there is a significantly increased prevalence of diabetes mellitus in adult GHD patients compared with the general population (46), particularly in those with additional risk factors, such as a family history of diabetes mellitus or obesity (47). The association between GHD and diabetes can be largely explained by adverse body compositions in patients with GHD. The increased abdominal obesity seen in GHD patients is likely a contributor to the decreased insulin sensitivity observed in some patients (48). GH is an important regulator of glucose levels, and adult patients with GHD are reported to have impaired glucose metabolism, insulin resistance, and fasting hyperglycemia (49, 50).
Hypertension
Hypertension is another reported risk factor for Covid-19 disease. Patients with raised blood pressure were found to have a twofold increased risk of death from COVID-19 compared to normotensive patients (51). In adult GHD, cardiovascular and cerebrovascular morbidity and mortality are increased, and this elevated risk can be largely attributed to hypertension (52). The beneficial effect of GH on cardiovascular risk factors in patients with hypopituitarism may be an indirect effect via alteration in cortisol metabolism (43). Previous studies described a close relationship between the GH/IGF-1 axis and the renin-angiotensin-aldosterone axis (RAS). GH has been shown to stimulate RAS as demonstrated by increasing levels of angiotensinogen, aldosterone, and plasma renin activity in human subjects (53). Angiotensin-Converting Enzyme 2 (ACE2), a cell membrane receptor in various target tissues, including the lung, catalyzes angiotensin II conversion to angiotensin-(1–7). The ACE2/angiotensin-(1–7)/MAS axis counteracts the negative effects of the renin-angiotensin system (RAS), thus playing an important role in maintaining the physiological and pathophysiological balance of the body (54). However, the upregulation of the (ACE2)/Angiotensin-(1-7)/Mas receptor axis has been recorded in the heart and the kidney of growth hormone receptor knock-out mice (55). On the other hand, downregulation of the ACE2/angiotensin-(1-7/MAS receptor axis has been recorded in the heart and kidney of transgenic mice overexpressing growth hormone (56). SARS-CoV-2 enters host cells via the ACE2 receptor, which is expressed in various human organs, and spike glycoprotein of SARS-CoV-2, which binds to ACE2, represents a potential target for developing specific drugs and vaccines (57). Besides the direct viral effects and inflammatory reactions associated with COVID-19 pathogenesis, ACE2 downregulation that follows COVID-19 infection and the consequent imbalance between the RAS and ACE2/angiotensin-(1–7)/MAS may also contribute to multiple organ injury in COVID-19 (58). Whether adult GHD leads to overexpression of ACE2 in vivo is not yet established by clinical studies.
Respiratory Disease
Meanwhile, in patients with bronchial asthma, it is reported that GH levels and response to GHRH are decreased. Low levels of the hormone are also associated with corticosteroid- and salbutamol-treated asthmatic patients (59).
Also, obese patients with obstructive sleep apnea syndrome (OSAS) demonstrate a peculiar reduction of both spontaneous and stimulated GH secretion coupled with reduced IGF-I levels. These endocrine abnormalities are more marked than those observed in nonapneic obese subjects and are likely to be due to the effects of hypoxia and sleep fragmentation on hormone secretory patterns. The GH/IGF-I axis activity disruption can be responsible, at least in part, for metabolic alterations, which are common in OSAS and increase the risk of cardiovascular events as well as mortality (60). In addition, the serum levels of IGF-1 are significantly reduced in patients with acute exacerbations of COPD (AECOPD) compared with other COPD patients (61) and then increase relatively at the time of recovery. However, the serum levels of IGF-1 both on admission and on the discharge of AECOPD patients are lower than those of healthy subjects (62). Moreover, emphysematous patients seem to have significantly lower IGF-1 levels compared to those with chronic bronchitis both on admission and at discharge (63).
Chronic Liver Disease
GH resistance is an increasingly recognized feature related to the reduction of IGF-I, IGF-II, and IGFBP-3 in liver dysfunction that may have been further pathogenically affected by the severity of liver dysfunction, the disorder of portosystemic shunting, and malnutrition of hepatic storage. In addition, the production/secretion of GH receptor was also markedly reduced due to severely damaged hepatocytes, thus leading to the disturbance of feedback maladjustment and GH resistance (64, 65). Patients with adult GHD show increased prevalence of nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH), and GH replacement therapy has been reported to improve these conditions (66). Meanwhile, the IGF-1 and IGFBP-3 levels were shown to be low in cirrhosis patients but to improve after liver transplantation (67).
Chronic Renal Disease
Chronic renal failure is associated with GH resistance and not GH deficiency (68). Suggested mechanisms of GH resistance in such conditions are reduced density of GH receptors in target tissues as indicated by low GHBP in children and adults with chronic kidney disease (CKD), which is proportionate to the degree of renal dysfunction (69), disturbed GH-activated post-receptor Janus kinase/signal transducer, and activator of transcription (JAK/STAT) signaling (70), and decreased levels of free IGF-1 due to increased inhibitory IGF-binding proteins (IGFBPs) (71). An important regulator of the JAK2/STAT pathway is the suppressor of cytokine signaling (SOCS) proteins, which is induced by GH. These proteins bind to JAK2 and inhibit STAT phosphorylation (72). The upregulation of SOCS has been described in inflammatory conditions and may play a similar role in chronic renal disease (73). The sodium and water-retaining effect of GH has been known for decades (74). Although the exact mechanism behind the antinatriuretic action of GH is not fully clarified, several direct and indirect mechanisms have been suggested. Both GH and IGF-I receptors are expressed in renal tubules (75), suggesting a direct effect of GH and IGF-I on sodium and water retention (76). GH deficiency in children and adults is associated with major changes in body composition, mainly presenting with an increase in subcutaneous and visceral fat mass and low sodium and water body content (77).
Chronic Alcohol Consumption
Moreover, high alcohol consumption was reported by the WHO to be a high-risk factor for severe Covid-19 illness. This remarkable note raises the possibility of a direct relationship between low consumption of alcohol in certain regions of the world and the limitation of the spread of the disease. The majority of effects of GH appear to be mediated indirectly through the enhanced synthesis and secretion of insulin-like growth factor (IGF)-I. Most studies have shown that chronic alcohol consumption in rodents or humans is associated with a decreased circulating concentration of IGF-I. Meanwhile, excessive alcohol intake has been shown to inhibit spontaneous pulsatile GH secretion (78).
It is, thus, worth noting that growth hormone deficiency and/or resistance could represent an epiphenomenon in potential risk groups for COVID-19 disease. GHD may be implicated in the severity and higher mortality of the disease in those groups of patients.
The Role of Growth Hormone in Immunity
Studies suggest that endocrine and neuroendocrine systems greatly influence the immune system (79). GH has an important role in the development of the immune system and may enhance the growth of the thymus gland which is responsible for the production of immune cells called T cells, the mediator of cell-mediated immunity (80). GH is also produced by lymphoid organs, such as the thymus, the spleen, and immune cells (81). Besides, clinical studies have suggested a significant role of GH in immune regulation, and the GH receptor is expressed on different subpopulations of lymphocytes (82). GH stimulates T and B cell proliferation and immunoglobulin formation. It enhances the maturation of myeloid progenitor cells and is also able to modulate cytokine response (83). A clinical study in 2012, demonstrated that lower circulating levels of IGF1 were associated with incidence and mortality from adult respiratory distress syndrome (ARDS). These data support the role of the IGF pathway in ARDS (84). Having an immune-regulatory effect in addition to their anabolic effects, growth hormone (GH) and insulin-like growth factor 1 (IGF-1), may act to protect the host from lethal bacterial infection as well. The hormones promote the maturation of myeloid cells, stimulate phagocyte migration, prime phagocytes for the production of superoxide anions and cytokines and enhance the opsonic activity (85).
Growth Hormone in Critically Ill Patients
Serum GH levels start to increase in the early hours after the onset of critical illness. Both frequency and amplitude of GH pulses are increased, associated with loss of the typical depressions during interpulse periods, which leads to elevated serum concentrations (86). In addition, the hepatic GH receptor function is suppressed. Peripheral GH resistance leads to low circulating levels of IGF-I, IGFBP-3, ALS, and GHBP (87). The combined effect of these alterations in the GH axis leads to a shift from the anabolic effects of IGF-I to more catabolic actions of GH, such as lipolysis, insulin resistance, and immune stimulation (88). When recovery does not start within a week and a chronic phase of critical illness ensues, the pulsatile pattern of GH secretion fades out, and GH peaks become blunted with IGF-I, IGFBP-3, and ALS levels remaining low. Interpulse GH concentrations also decrease but still appear to be higher than in healthy subjects (89). In the acute phase of critical illness, hepatic GH resistance is responsible for altering the GH axis. Whereas, during the prolonged phase of critical illness, the fall in GH is thought to be caused by an impaired hypothalamic drive. Hepatic GH resistance does not appear to persist during chronic critical illness (90). This is supported by a high GH responsiveness to the administration of GH secretagogues (GHRPs) in chronic critically ill patients. In fact, restoration of pulsatile GH secretion pattern associated the administration of GHRP, alone or with the coadministration of GHRH, leading to a sixfold and tenfold increase in amplitudes of GH serum peaks, respectively. Strikingly, the administration of GHRH alone is not capable of restoring the typical pulsatile pattern of GH secretion (91). Another suggested contributor to the attenuated GH levels during chronic critical illness is the scarcity of the active form of ghrelin, the endogenous ligand of the GH secretagogue receptor, and a powerful GH secretagogue (92). The low serum IGF-I and its binding proteins are associated with biochemical markers of impaired anabolism, such as low serum osteocalcin and leptin (93).
A large randomized clinical trial, investigating the effect of high-dose GH injection to prolonged critically ill patients, unexpectedly recorded a doubling in mortality in the intervention cohort (94). Because GH resistance at least partially resolves in the chronic phase, it is likely that such high doses of GH and, consequently, high levels of IGF-I, evoke toxic side effects, such as excessive fluid retention, hypercalcemia, and pronounced insulin resistance with hyperglycemia. Although small studies show the ability of GHRP-2 to restore a normal GH pulsatile pattern in severely ill patients, and of the combination of GHRP-2 and thyrotropin-releasing hormone (TRH) to induce an anabolism and suppress catabolism in prolonged critically ill patients (95), the clinical outcome of infusion with GH secretagogues has not yet been studied. Also, substitution with ghrelin has recently been investigated in smaller animals and in vitro studies and appeared to enhance autophagy, reduce catabolism, and improve hemodynamics (96). As ghrelin induces appetite, infusion of ghrelin during the chronic phase of critical illness when patients restart oral intake may enhance food intake and could lead to an improvement in clinical outcomes (97). Large-scale RCTs in humans, to corroborate these findings, have not yet been performed.
Growth Hormone and Cancer Risk
The use of GH, especially in non-GHD persons, has raised safety concerns regarding the cancer risk because IGF-I has potent mitogenic and antiapoptotic effects. However, the results of epidemiological, experimental, and observational studies are ambiguous. A number of biases and confounders affect the interpretation of data (98). Nevertheless, the concern of cancer risk associating administration of r-HGH is related to long-term therapy, especially in children with GHD and in particular, those who recovered from malignancy for fear of recurrence.
Adverse Effects of GH Treatment
Older persons are more sensitive to replacement with GH and more susceptible to the side effects of therapy. The acute side effects are due to the hormonal effects of over-replacement, which can be avoided or relieved with careful dose titration. Patients who are older, heavier, or female are more prone to develop complications (99). Common side effects of GH replacement include fluid retention, peripheral edema, arthralgia, and carpal tunnel syndrome. Although glucose levels often increase with the initiation of GH, these levels generally return toward normal with the improvement in body composition and reduced insulin resistance. Other, less frequently reported side effects are headache, tinnitus, and benign intracranial hypertension (99). Whether increasing growth hormone above the age-appropriate normal range may have as many risks, both acute and delayed, as benefits is a worthwhile hypothesis to examine.
Conclusion
In conclusion, we have observed some characteristic distribution of the severity of the disease COVID-19 that seems to be matched with a relative deficiency and/or resistance of growth hormone in some groups of patients. We wanted to share that note with the medical community so that it may add to the urgent efforts to understand and consequently overcome the pandemic. We think that there is a need for further studying the role of growth hormone in the unique epidemiological pattern of COVID-19 so that it can help in the early detection and management of the high-risk groups. A randomized controlled trial would help clarify the possible prophylactic role of growth hormone supplement in those groups of patients to alleviate immunity and decrease the severity and/or mortality of the disease till an efficient vaccine is available in the market worldwide.
Data Availability Statement
The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.
Author Contributions
All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1. Reid A. The Effects of the 1918–1919 Influenza Pandemic on Infant and Child Health in Derbyshire. Med History (2005) 49(1):29–54. doi: 10.1017/S0025727300008279
2. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). 16-20th February 2020: Major findings, chapter 2, page12. World health organization (WHO) (2020). Available at: https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf.
3. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis (2020) 20(6):P669–77. doi: 10.1016/S1473-3099(20)30243-7
4. Merriam GR, Hersch EC. Growth hormone (GH)-releasing hormone and GH secretagogues in normal aging: Fountain of Youth or Pool of Tantalus? Clin Interv Aging (2008) 3(1):121–9. doi: 10.2147/CIA.S3247
5. Gotzinger F, Santiago-Garcia B, Noguera-Julian A, Lanaspa M, Lancella L, Calo Carducci FI, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health (2020) 4(9):653–61. doi: 10.1016/S2352-4642(20)30177-2
6. Mehta N, Kalra A, Nowacki AS, Anjewierden S, Han Z, Bhat P, et al. Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol (2020) 5(9):1020–6. doi: 10.1001/jamacardio.2020.1855
7. Oualha M, Bendavid M, Berteloot L, Corsia A, Lesage F, Vedrenne M, et al. Severe and fatal forms of COVID-19 in children. Arch Pediatr (2020) 27:235–8. doi: 10.1016/j.arcped.2020.05.010
8. Shekerdemian LS, Mahmood NR, Wolfe KK, Riggs BJ, Ross CE, McKiernan CA, et al. Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units. JAMA Pediatr (2020) 174(9):868–73. doi: 10.1001/jamapediatrics.2020.1948
9. Sun D, Li H, Lu XX, Xiao H, Ren J, Zhang F-R, et al. Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center’s observational study. World J Pediatr (2020) 16:251–9. doi: 10.1007/s12519-020-00354-4
10. Leger J, Noel M, Limal JM, Czernichow P. Growth factors and intrauterine growth retardation. II. Serum growth hormone, insulin-like growth factor (IGF) I, and IGF-binding protein 3 levels in children with intrauterine growth retardation compared with normal control subjects: prospective study from birth to two years of age. Study Group of IUGR. Pediatr Res (1996) 40(1):101–7. doi: 10.1203/00006450-199607000-00018
11. Sherlock M, Toogood AA. Aging and the growth hormone/insulin like growth factor-I axis. Pituitary (2007) 10(2):189–203. doi: 10.1007/s11102-007-0039-5
12. Young A. Coronavirus:why-do-more-men-die-of-covid-19-than-women. (2020). Available at: https://globalhealth5050.org/the-sex-gender-and-covid-19-project/.
13. Johansson AG. Gender difference in growth hormone response in adults. J Endocrinol Invest (1999) 22(5 Suppl):58–60. PMID: 10442572
14. Chernecky CC, Berger BJ. Laboratory Tests and Diagnostic Procedures. 6th ed. St Louis, MO: Elsevier Saunders (2013) p. 599–600. Available at: https://www.ucsfhealth.org/medical-tests/growth-hormone-test.
15. Stanworth RD, Jones TH. Testosterone for the aging male; current evidence and recommended practice. Clin Interv Aging (2008) 3(1):25–44. doi: 10.2147/cia.s190
16. Garcia JM, Merriam GR, Kargi AY, Feingold KR, Anawalt B, Boyce A, et al. Growth Hormone in Aging. In: Endotext [Internet], Feingold KR, Anawalt B, Boyce A, editors. South Dartmouth (MA): MDText.com (2000). Available at: https://www.ncbi.nlm.nih.gov/books/NBK279163/.
17. Meinhardt UJ, Ho KK. Modulation of growth hormone action by sex steroids. Clin Endocrinol (Oxf) (2006) 65(4):413–22. doi: 10.1111/j.1365-2265.2006.02676.x
18. van den Berg G, Veldhuis JD, Frolich M. Roelfsema F 1996 An amplitude-specific divergence in the pulsatile mode of growth hormone (GH) secretion underlies the gender difference in mean GH concentrations in men and premenopausal women. J Clin Endocrinol Metab (1996) 81:2460–7. doi: 10.1210/jcem.81.7.8675561
19. Weltman A, Weltman JY, Hartman ML, Abbott RD, Rogol AD, Evans WS, et al. Relationship between age, percentage body fat, fitness, and 24-hour growth hormone release in healthy young adults: effects of gender. J Clin Endocrinol Metab (1994) 78:543–54810. doi: 10.1210/jcem.78.3.8126124
20. Vahl N, Jørgensen JOL, Skjærbæk C, Veldhuis JD, Ørskov H. Christiansen JS 1997 Abdominal adiposity rather than age and sex predicts mass and regularity of GH secretion in healthy adults. Am J Physiol (1997) 272:E1108–16. doi: 10.1152/ajpendo.1997.272.6.E1108
21. Clasey JL, Weltman A, Patrie J, Weltman JY, Pezzoli S, Bouchard C, et al. Abdominal visceral fat and fasting insulin are important predictors of 24-hour GH release independent of age, gender, and other physiological factors. J Clin Endocrinol Metab (2001) 86:3845–52. doi: 10.1210/jcem.86.8.7731
22. Baumann G. Growth hormone binding protein. J Pediatr Endocrinol Metab (2001) 14:355–75. doi: 10.1515/JPEM.2001.14.4.355
23. Rajkovic I, Valiontis E, Ho KKY. Direct quantitation of growth hormone binding protein in human serum by a ligand immunofunctional assay: comparison with immunoprecipitation and chromatographic methods. J Clin Endocrinol Metab (1994) 78:772–7777. doi: 10.1210/jcem.78.3.8126156
24. Serri O, St-Jacques P, Sartippour M, Renier G. Alterations of monocyte function in patients with growth hormone (GH) deficiency: effect of substitutive GH therapy. J Clin Endocrinol Metab (1999) 84:58–63. doi: 10.1210/jc.84.1.58
25. Sesmilo G, Biller BM, Llevadot J, Hayden D, Hanson G, Rifai N, et al. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med (2000) 133:111–22. doi: 10.7326/0003-4819-133-2-200007180-00010
26. Sesmilo G, Fairfield WP, Katznelson L, Pulaski K, Freda PU, Bonert V, et al. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. J Clin Endocrinol Metab (2002) 87:1692–9. doi: 10.1210/jcem.87.4.8364
27. Leung KC, Doyle N, Ballesteros M, Sjogren K, Watts CK, Low TH, et al. Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2. Proc Natl Acad Sci USA (2003) 100:1016–102. doi: 10.1073/pnas.0337600100
28. Giamarellos-Bourboulis EJ. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe (2020) 27:992–1000. doi: 10.1016/j.chom.2020.04.009
29. Hirano T, Murakami M. COVID-19: a new virus, but a familiar receptor and cytokine release syndrome. Immunity (2020) 52:731–3. doi: 10.1016/j.immuni.2020.04.003
30. Zhou F. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (2020) 395:1054–62. doi: 10.1016/S0140-6736(20)30566-3
31. Ruan Q. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intens Care Med (2020) 46:846–8. doi: 10.1007/s00134-020-05991-x
32. Luo W, Li YX, Jiang LJ, Chen Q, Wang T, Ye DW. Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19. Trends Pharmacol Sci (2020) 41(8):531–43. doi: 10.1016/j.tips.2020.06.007
33. Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, et al. Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US. JAMA Intern Med (2020) e203596. doi: 10.1001/jamainternmed.2020.3596. Online ahead of print.
34. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med (2020) 8:e21. doi: 10.1016/S2213-2600(20)30116-8
35. Alqahtani JS, Oyelade T, Aldhahir AM, Alghamdi SM, Almehmadi M, Alqahtani AS, et al. Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: a rapid systematic review and meta-analysis. PloS One (2020) 15:e0233147. doi: 10.1371/journal.pone.0233147
36. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. High Prevalence of Obesity in Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation. Obes (Silver Spring) (2020) 28(7):1195–9. doi: 10.1002/oby.22831
37. Alvarez P, Isidro L, Leal-Cerro A, Casanueva FF, Dieguez C, Cordido F, et al. Effect of withdrawal of somatostatin plus GH-releasing hormone as a stimulus of GH secretion in obesity. Clin Endocrinol (Oxf) (2002) 56(4):487–92. doi: 10.1046/j.1365-2265.2002.01487.x
38. Iranmanesh A, Lizarralde G, Veldhuis JD. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. J Clin Endocrinol Metab (1991) 73(5):1081–8. doi: 10.1210/jcem-73-5-1081
39. Veldhuis JD, Iranmanesh A, Ho KK, Waters MJ, Johnson ML, Lizarralde G. Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man. J Clin Endocrinol Metab (1991) 72(1):51–9. doi: 10.1210/jcem-72-1-51
40. Williams T, Berelowitz M, Joffe SN, Thorner MO, Rivier J, Vale W, et al. Impaired growth hormone responses to growth hormone-releasing factor in obesity. A pituitary defect reversed with weight reduction. N Engl J Med (1984) 311(22):1403–7. doi: 10.1056/NEJM198411293112203
41. Vahl N, Jorgensen JO, Jurik AG, Christiansen JS. Abdominal adiposity and physical fitness are major determinants of the age associated decline in stimulated GH secretion in healthy adults. J Clin Endocrinol Metab (1996) 81(6):2209–15. doi: 10.1210/jcem.81.6.8964853
42. Clasey JL, Weltman A, Patrie J, Weltman JY, Pezzoli S, Bouchard C, et al. Abdominal visceral fat and fasting insulin are important predictors of 24-hour GH release independent of age, gender, and other physiological factors. J Clin Endocrinol Metab (2001) 86(8):3845–52. doi: 10.1210/jcem.86.8.7731
43. Stewart PM, Toogood AA, Tomlinson JW. Growth hormone, insulin-like growth factor-I and the cortisol-cortisone shuttle. Horm Res (2001) 56 Suppl 1:1–6. doi: 10.1159/000048126
44. Gelding SV, Taylor NF, Wood PJ, Noonan K, Weaver JU, Wood DF, et al. The effect of growth hormone replacement therapy on cortisol-cortisone interconversion in hypopituitary adults: evidence for growth hormone modulation of extrarenal 11β-hydroxysteroid dehydrogenase activity. Clin Endocrinol (Oxf) (1998) 48:153–62. doi: 10.1046/j.1365-2265.1998.3641180.x
45. Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia - A systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr (2020) 14(4):395–403. doi: 10.1016/j.dsx.2020.04.018
46. Abs R, Mattsson AF, Thunander M, Verhelst J, Goth MI, Wilton P, et al. Prevalence of diabetes mellitus in 6050 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis. Eur J Endocrinol (2013) 168:297–305. doi: 10.1530/eje-12-0807
47. Allen DB, Backeljauw P, Bidlingmaier M, Biller BM, Boguszewski M, Burman P, et al. GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. Eur J Endocrinol (2016) 174:P1–9. doi: 10.1530/EJE-15-0873
48. Feldt-Rasmussen U, Klose M, Feingold KR, Anawalt B, Boyce A, Chrousos G, et al. Adult growth hormone deficiency clinical management. In: Endotext, De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, editors. South Dartmouth (MA: MDText.com, Inc (2000). Available at: https://www.ncbi.nlm.nih.gov/books/NBK425701/.
49. Giovannini L, Tirabassi G, Muscogiuri G, Di Somma C, Colao A, Balercia G. Impact of adult growth hormone deficiency on metabolic profile and cardiovascular risk [review]. Endocr J (2015) 62:1037–48. doi: 10.1507/endocrj.EJ15-0337
50. Kim SH, Park MJ. Effects of growth hormone on glucose metabolism and insulin resistance in human. Ann Pediatr Endocrinol Metab (2017) 22:145–52. doi: 10.6065/apem.2017.22.3.145
51. Chao G, Cai Y, Zhang K, Zhou L, Zhang Y, Zhang X, et al. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. Eur Heart J (2020) 41(22):2058–66. doi: 10.1093/eurheartj/ehaa433
52. Daniel HPT, Merriam GR. Endocrine hypertension: Underlying mechanisms and therapy .Hypertension in Growth Hormone Excess and Deficiency. July (2012) 7:151–79. doi: 10.1007/978-1-60761-548-4_8
53. Ho KY, Weissberger AJ. The antinatriuretic action of biosynthetic human growth hormone in man involves activation of the renin-angiotensin system. Metabolism (1990) 39:133–7. doi: 10.1016/0026-0495(90)90065-K
54. Santos R, Sampaio W, Alzamora A, Motta-Santos D, Alenina N, Bader M, et al. The ACE2/angiotensin-(1-7)/MAS axis of the renin-angiotensin system: focus on angiotensin-(1-7). Physiol Rev (2018) 98:505–53. doi: 10.1152/physrev.00023.2016
55. Giani JF, Miquet JG, Muñoz MC, Burghi V, Toblli JE, Masternak MM, et al. Upregulation of the angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas receptor axis in the heart and the kidney of growth hormone receptor knock-out mice. Growth Horm IGF Res (2012) 22(6):224–33. doi: 10.1016/j.ghir.2012.08.003
56. Muñoz MC, Burghi V, Miquet JG, Giani JF, Banegas RD, Toblli JE, et al. Downregulation of the ACE2/Ang-(1-7)/Mas axis in transgenic mice overexpressing GH. J Endocrinol (2014) 221(2):215–27. doi: 10.1530/JOE-13-0497
57. Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science (2020) 367:1260–3. doi: 10.1126/science.abb2507
58. Ni W, Yang X, Yang D, Bao J, Li R, Xiao Y, et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care (2020) 24:422. doi: 10.1186/s13054-020-03120-0
59. Malerba M, Bossoni S, Radaeli A, Mori E, Bonadonna S, Giustina A, et al. Growth hormone response to growth hormone-releasing hormone is reduced in adult asthmatic patients receiving long-term inhaled corticosteroid treatment. Chest (2005) 127(2):515–21. doi: 10.1378/chest.127.2.515
60. Lanfranco F, Motta G, Minetto MA, Ghigo E, Maccario M. Growth hormone/insulin-like growth factor-I axis in obstructive sleep apnea syndrome: An update. J Endocrinol Invest (2010) 33:192–6. doi: 10.1007/BF03346580
61. Ye M, Yu H, Yu W, Zhang G, Xiao L, Zheng X, et al. Evaluation of the significance of circulating insulin-like growth factor-1 and C-reactive protein in patients with chronic obstructive pulmonary disease. J Int Med Res (2012) 40(3):1025–35. doi: 10.1177/147323001204000321
62. Corbo GM, Di Marco Berardino A, Mancini A, Inchingolo R, Smargiassi A, Raimondo S, et al. Serum level of testosterone, dihydrotestosterone and IGF-1 during an acute exacerbation of COPD and their relationships with inflammatory and prognostic indices: a pilot study. Minerva Med (2014) 105(4):289–94. PMID: 24844347
63. Kythreotis P, Kokkini A, Avgeropoulou S, Hadjioannou A, Anastasakou E, Rasidakis A, et al. Plasma leptin and insulin-like growth factor I levels during acute exacerbations of chronic obstructive pulmonary disease. BMC Pulm Med (2009) 9:11. doi: 10.1186/1471-2466-9-11
64. Ottesen LH, Bendtsen F, Flyvbjerg A. The insulin-like growth factor binding protein 3 ternary complex is reduced in cirrhosis. Liver (2001) 21:350–6. doi: 10.1034/j.1600-0676.2001.210508.x
65. Fernández-Rodriguez CM, Prada I, Andrade A, Moreiras M, Guitián R, Aller R, et al. Disturbed synthesis of insulinlike growth factor I and its binding proteins may influence renal function changes in liver cirrhosis. Dig Dis Sci (2001) 46:1313–20. doi: 10.1023/A:1010631800505
66. Takahashi Y. The Role of Growth Hormone and Insulin-Like Growth Factor-I in the Liver. Int J Mol Sci (2017) 18:1447. doi: 10.3390/ijms18071447
67. Castro GR, Coelho JC, Parolin MB, Matias JEF, de Freitas ACT. Insulin-like growth factor I correlates with MELD and returns to normal level after liver transplantation. Ann Transplant (2013) 18:57–62. doi: 10.12659/AOT.883819
68. Mahesh S, Kaskel F. Growth hormone axis in chronic kidney disease. Pediatr Nephrol (2008) 23(1):41–8. doi: 10.1007/s00467-007-0527-x
69. Tonshoff B, Cronin MJ, Reichert M, Haffner D, Wingen AM, Blum WF, et al. Reduced concentration of serum growth hormone (GH)–binding protein in children with chronic renal failure: correlation with GH insensitivity. The European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood. The German Study Group for Growth Hormone Treatment in Chronic Renal Failure. J Clin Endocrinol Metab (1997) 82(4):1007–13. doi: 10.1210/jcem.82.4.3893
70. Rabkin R, Sun DF, Chen Y, Tan J, Schaefer F. Growth hormone resistance in uremia, a role for impaired JAK/STAT signaling. Pediatr Nephrol (2005) 20(3):313–8. doi: 10.1007/s00467-004-1713-8
71. Tonshoff B, Blum WF, Mehls O. Serum insulin-like growth factors and their binding proteins in children with end-stage renal disease. Pediatr Nephrol (1996) 3:269–74. doi: 10.1007/BF00866755
72. Wormald S, Hilton DJ. Inhibitors of cytokine signal transduction. J Biol Chem (2004) 279(2):821–4. doi: 10.1074/jbc.R300030200
73. Kaysen GA. The microinflammatory state in uremia: causes and potential consequences. J Am Soc Nephrol (2001) 12(7):1549–57. PMID: 11423586
74. Ikkos D, Luft R. Sjögren B 1954 Body water and sodium in patients with acromegaly. J Clin Invest (1954) 33:989–94. doi: 10.1172/JCI102977
75. Chin E, Zhou J, Bondy CA. Renal growth hormone receptor gene expression: relationship to renal insulin-like growth factor system. Endocrinology (1992) 131:3061–6. doi: 10.1210/endo.131.6.1446640
76. Blazer-Yost BL. Cox M 1988 Insulin-like growth factor 1 stimulates renal epithelial Na+ transport. Am J Physiol (255) 225:C413–7. doi: 10.1152/ajpcell.1988.255.3.C413
77. Møller J. Effects of growth hormone on fluid homeostasis. Clinical and experimental aspects. Growth Horm IGF Res (2003) 13:55–74. doi: 10.1016/S1096-6374(03)00011-X
78. Lang CH, Liu X, Nystrom G, Wu D, Cooney RN, Frost RA. ACUTE EFFECTS OF GROWTH HORMONE IN ALCOHOL-FED RATS. Alcohol Alcohol (2000) 35(2):148–58. doi: 10.1093/alcalc/35.2.148
79. Tang MW, Garcia S, Gerlag DM, Tak PP, Reedquist KA. Insight into the endocrine system and the immune system: a review of the inflammatory role of prolactin in rheumatoid arthritis and psoriatic arthritis. Front Immunol (2017) 8:720:720. doi: 10.3389/fimmu.2017.00720
80. Napolitano LA, Schmidt D, Gotway MB, Ameli N, Filbert EL, Ng MM, et al. Growth hormone enhances thymic function in HIV-1-infected adults. J Clin Invest (2008) 118(3):1085–98. doi: 10.1172/JCI32830
81. Savino W, Postel-Vinay MC, Smaniotto S, Dardenne M. The thymus gland: a target organ for growth hormone. Scand J Immunol (2002) 55:442–52. doi: 10.1046/j.1365-3083.2002.01077.x
82. Hattori N, Saito T, Yagyu T, Jiang BH, Kitagawa K, Inagaki CGH. GH receptor, GH secretagogue receptor, and ghrelin expression in human T cells, B cells, and neutrophils. J Clin Endocrinol Metab (2001) 86:4284–91. doi: 10.1210/jcem.86.9.7866
83. Meazza C, Pagani S, Travaglino P, Bozzola M. Effect of growth hormone (GH) on the immune system. Pediatr Endocrinol Rev (2004) 1 Suppl 3:490–5. PMID: 16444180
84. Ahasic AM, Zhai R, Su L, Zhao Y, Aronis KN, Thompson BT, et al. IGF1 and IGFBP3 in acute respiratory distress syndrome [published correction appears in Eur J Endocrinol. 2014 Nov;171(5):X4]. Eur J Endocrinol (2012) 166(1):121–9. doi: 10.1530/EJE-11-0778
85. Saito H, Inoue T, Fukatsu K, Ming-Tsan L, Inaba T, Fukushima R, et al. Growth hormone and the immune response to bacterial infection. Horm Res (1996) 45(1-2):50–4. doi: 10.1159/000184759
86. Teng Chung T, Hinds CJ. Treatment with GH and IGF-1 in critical illness. Crit Care Clinics (2006) 22:29–40. doi: 10.1016/j.ccc.2005.09.003
87. Timmins AC, Cotterill AM, Hughes SC, Holly JM, Ross RJ, Blum W, et al. Critical illness is associated with low circulating concentrations of insulin-like growth factors-I and -II, alterations in insulin-like growth factor binding proteins, and induction of an insulin-like growth factor binding protein 3 protease. Crit Care Med (1996) 24:1460–6. doi: 10.1097/00003246-199609000-00006
88. Bentham J, Rodriguez-Arnao J, Ross RJ. Acquired growth hormone resistance in patients with hypercatabolism. Hormone Res (1993) 40:87–91. doi: 10.1159/000183772
89. Van den Berghe G, de Zegher F, Veldhuis JD, Wouters P, Awouters M, Verbruggen W, et al. The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion. J Clin Endocrinol Metab (1997) 82:590–9. doi: 10.1210/jcem.82.2.3736
90. Van den Berghe G. Growth hormone secretagogues in critical illness. Hormone Res (1999) 51(Supplement 3):21–8. doi: 10.1159/000053158
91. Van den Berghe G, de Zegher F, Baxter RC, Veldhuis JD, Wouters P, Schetz M, et al. Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues. J Clin Endocrinol Metab (1998) 83:309–19. doi: 10.1210/jcem.83.2.4575
92. Hill NE, Murphy KG, Singer M. Ghrelin, appetite and critical illness. Curr Opin Crit Care (2012) 18:199–205. doi: 10.1097/MCC.0b013e3283514b01
93. Van den Berghe G, Wouters P, Weekers F, Mohan S, Baxter RC, Veldhuis JD, et al. Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. J Clin Endocrinol Metab (1999) 84:1311–23. doi: 10.1210/jc.84.4.1311
94. Takala J, Ruokonen E, Webster NR, Nielsen MS, Zandstra DF, Vundelinckx G, et al. Increased mortality associated with growth hormone treatment in critically ill adults. New Engl J Med (1999) 341:785–92. doi: 10.1056/NEJM199909093411102
95. Van den Berghe G, de Zegher F, Bowers CY, Wouters P, Muller P, Soetens F, et al. Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness. Clin Endocrinol (1996) 45:341–51. doi: 10.1046/j.1365-2265.1996.00805.x
96. Zhou M, Aziz M, Ochani M, Yang WL, Sharma A, Wang P. The protective role of human ghrelin in sepsis: restoration of CD4 T cell proliferation. PloS One (2018) 13:e0201139. doi: 10.1371/journal.pone.0201139
97. Narula T, deBoisblanc BP. Ghrelin in critical illness. Am J Respiratory Cell Mol Biol (2015) 53:437–42. doi: 10.1165/rcmb.2014-0226TR
98. Cianfarani S. Risk of cancer in patients treated with recombinant human growth hormone in childhood. Ann Pediatr Endocrinol Metab (2019) 24(2):92–8. doi: 10.6065/apem.2019.24.2.92
Keywords: coronavirus pandemic, COVID-19, growth hormone, IGF-1, immune system, epidemiology, risk factors
Citation: Elkarow MH and Hamdy A (2020) A Suggested Role of Human Growth Hormone in Control of the COVID-19 Pandemic. Front. Endocrinol. 11:569633. doi: 10.3389/fendo.2020.569633
Received: 05 June 2020; Accepted: 17 September 2020;
Published: 09 November 2020.
Edited by:
Rosario Pivonello, University of Naples Federico II, ItalyReviewed by:
Silvia Grottoli, University of Turin, ItalyMauro Antonio Czepielewski, Federal University of Rio Grande do Sul, Brazil
Copyright © 2020 Elkarow and Hamdy. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Mohamed Hamdy Elkarow, aGFtZHlkb2N0b3I3ODVAZ21haWwuY29t